Botox injections make wrinkles look better for the first few years, but after 15 years, everyone’s wrinkles look about the same no matter how often or how young they started getting injections.
Scientific Claim
Over a 15-year computational simulation, botulinum toxin A administered biannually or triannually reduces wrinkle depth in the forehead, glabellar, and lateral canthal regions during the first five years, but these reductions are not sustained beyond year five, with all treatment groups converging to similar wrinkle depths (~1.0 mm) by year 15 regardless of age at initiation or injection frequency.
Original Statement
“Wrinkle depth decreased in all groups during the first five years... However, by year 15, wrinkle depths rebounded and converged across all cohorts (~1.0 mm).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes simulated model outputs under defined parameters; since the study is computational and no causal claims about human biology are made here, definitive language is appropriate for the model's behavior.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether long-term BoNTA use (≥10 years) alters the trajectory of wrinkle progression compared to no treatment in diverse human populations.
Whether long-term BoNTA use (≥10 years) alters the trajectory of wrinkle progression compared to no treatment in diverse human populations.
What This Would Prove
Whether long-term BoNTA use (≥10 years) alters the trajectory of wrinkle progression compared to no treatment in diverse human populations.
Ideal Study Design
A systematic review and meta-analysis of 15+ year prospective cohort studies involving 5,000+ adults aged 20–50 at baseline, comparing wrinkle depth (measured via 3D photogrammetry) in those receiving regular BoNTA (biannual/triannual) versus no neuromodulator treatment, controlling for sun exposure, smoking, and skin type.
Limitation: Cannot isolate BoNTA effects from concurrent skincare or lifestyle interventions.
Longitudinal Cohort StudyLevel 2bThe natural progression of facial wrinkling over 15 years in individuals receiving consistent BoNTA versus those who do not.
The natural progression of facial wrinkling over 15 years in individuals receiving consistent BoNTA versus those who do not.
What This Would Prove
The natural progression of facial wrinkling over 15 years in individuals receiving consistent BoNTA versus those who do not.
Ideal Study Design
A prospective cohort study of 1,000 healthy adults aged 25–45, randomized to receive biannual BoNTA or no treatment for 15 years, with standardized 3D facial imaging, collagen density (biopsy), and dermal thickness (ultrasound) measured annually.
Limitation: Prone to attrition bias and confounding by concurrent aesthetic treatments.
Randomized Controlled TrialLevel 1bCausal effect of BoNTA frequency on long-term wrinkle development compared to placebo.
Causal effect of BoNTA frequency on long-term wrinkle development compared to placebo.
What This Would Prove
Causal effect of BoNTA frequency on long-term wrinkle development compared to placebo.
Ideal Study Design
A double-blind, placebo-controlled RCT of 300 adults aged 30–40, randomized to biannual BoNTA, triannual BoNTA, or placebo injections for 15 years, with primary outcome: change in glabellar wrinkle depth via 3D imaging at year 15.
Limitation: Ethical and logistical challenges in maintaining 15-year blinding and compliance.
Case-Control StudyLevel 3Association between decades of BoNTA use and severity of facial aging in older adults.
Association between decades of BoNTA use and severity of facial aging in older adults.
What This Would Prove
Association between decades of BoNTA use and severity of facial aging in older adults.
Ideal Study Design
A case-control study comparing 200 adults aged 65+ with ≥10 years of BoNTA use to 200 matched controls with no history of neuromodulators, assessing facial aging via standardized photographic scoring and skin biopsies.
Limitation: Retrospective recall bias and selection bias in treatment history.
Longitudinal Animal Model StudyLevel 4Biological mechanism of BoNTA on dermal aging pathways over time.
Biological mechanism of BoNTA on dermal aging pathways over time.
What This Would Prove
Biological mechanism of BoNTA on dermal aging pathways over time.
Ideal Study Design
A 15-year longitudinal study in aged mice or non-human primates receiving repeated BoNTA injections (biannual) versus saline, measuring collagen synthesis, fibroblast senescence, and ECM remodeling via histology and molecular assays.
Limitation: Limited translatability to human facial anatomy and aging dynamics.
Evidence from Studies
Supporting (1)
A 15-Year Computational Twin Modeling Study of Botulinum Toxin A Frequency and Age-Related Facial Aging.
The study used computer models to simulate what happens when people get Botox shots every 6 or 8 months for 15 years. It found that Botox smooths wrinkles at first, but after 5 years, everyone’s wrinkles come back to about the same depth — no matter when they started or how often they got shots.